documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,449 rows where document_type = "Other" and posted_year = 2006 sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: posted_month, open_for_comment, withdrawn, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)

posted_year 1

  • 2006 · 1,449 ✖

document_type 1

  • Other · 1,449 ✖

agency_id 1

id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2006-P-0325-0002 FDA Amend 21 C.F.R. 312. Promotion & Charging for Investigational Drugs Re: Pandemic Vaccine-CLOSED FDA-2006-P-0325 Acknowledgement Letter from FDA DMB to Vaccine for All LLC Other Acknowledgement Letter/Receipt 2006-12-29T05:00:00Z 2006 12     2024-12-10T17:14:33Z   0 0 090000648045ce8c
FDA-2006-N-0100-0018 FDA FDA-Regulated Products Containing Nanotechnology Materials FDA-2006-N-0100 National Cancer Institute Other TS-Testimony 2006-12-29T05:00:00Z 2006 12     2008-04-11T23:09:24Z   0 0 090000648044504a
FDA-2006-P-0325-0001 FDA Amend 21 C.F.R. 312. Promotion & Charging for Investigational Drugs Re: Pandemic Vaccine-CLOSED FDA-2006-P-0325 Acknowledgement Letter from FDA DMB to Vaccine for All LLC Other Acknowledgement Letter/Receipt 2006-12-29T05:00:00Z 2006 12     2024-12-10T17:14:04Z   0 0 090000648045ce69
FDA-2006-P-0003-0003 FDA Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products FDA-2006-P-0003 FDA/OC to CoMed, Coalition for Mercury-Free Drugs Other LET-Letter 2006-12-28T05:00:00Z 2006 12     2008-04-11T23:16:24Z   0 0 09000064804413d6
FDA-2006-P-0003-0001 FDA Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products FDA-2006-P-0003 FDA/DDM to CoMed, Coalition for Mercury-Free Drugs Other ACK-Acknowledgement Letter 2006-12-28T05:00:00Z 2006 12     2008-04-11T23:16:24Z   0 0 09000064804413a7
FDA-2004-P-0001-0007 FDA Citizen Petition Requesting Certain Actions with Respect to Vaccines & Other Drug Products, Containing Added Mercury, In Order to Reduce the Health Risk to Susceptible Fetuses, Newborns, Children, Adolescents & Adults-CLOSED FDA-2004-P-0001 FDA/CBER Response to Coalition for Mercury-Free Drugs (CoMeD) - Answer Other ANS-Answer 2006-12-28T05:00:00Z 2006 12     2009-10-19T19:01:20Z   0 0 090000648046a67e
FDA-2006-P-0003-0002 FDA Ban From all Medicine and Vaccines Thimerosal or any Other Mercury-based Compound Products FDA-2006-P-0003 FDA/DDM to CoMed, Coalition for Mercury-Free Drugs Other ACK-Acknowledgement Letter 2006-12-28T05:00:00Z 2006 12     2008-04-11T23:16:23Z   0 0 09000064804413d5
FDA-1996-N-0028-0037 FDA Current Good Manufacturing Practice in Manufacturing, Packing, or Holding Dietary Supplements FDA-1996-N-0028 FDA Office of Policy to the Docket, 12/26/2006 (re Meeting on September 20, 2006 between the Food and Drug Administration and the Natural Products Association) - Memorandum Meeting Other MM-Memorandum of Meeting 2006-12-28T05:00:00Z 2006 12     2009-09-11T19:52:51Z   0 0 09000064804fbfa5
FDA-2006-P-0344-0002 FDA FDA-2006-P-0344 Acknowledgment Letter from FDA DMB to King & Spalding LLP Other Acknowledgement Letter/Receipt 2006-12-27T05:00:00Z 2006 12     2024-12-10T15:26:25Z   0 0 090000648045f14e
FDA-2006-P-0344-0001 FDA FDA-2006-P-0344 Acknowledgment Letter from FDA DMB to King & Spalding LLP Other Acknowledgement Letter/Receipt 2006-12-27T05:00:00Z 2006 12     2024-12-10T15:25:34Z   0 0 090000648045f12b
FDA-2006-P-0146-0002 FDA ANDA for Sterile Vancomycin Hydrochloride USP, 750 mg-CLOSED FDA-2006-P-0146 Acknowledgment Letter from FDA DMB to King and Spalding, LLP Other Acknowledgement Letter/Receipt 2006-12-27T05:00:00Z 2006 12     2024-12-10T16:05:27Z   0 0 09000064804504bc
FDA-2006-P-0146-0001 FDA ANDA for Sterile Vancomycin Hydrochloride USP, 750 mg-CLOSED FDA-2006-P-0146 Acknowledgment Letter from FDA DMB to King and Spalding, LLP Other Acknowledgement Letter/Receipt 2006-12-27T05:00:00Z 2006 12     2024-12-10T16:01:23Z   0 0 09000064804504ab
FDA-2006-E-0322-0001 FDA Patent Extension Application for Anthelios SX Daily Moisturizing Cream With Sunscreen, U.S. Patent No. 4,585,597 FDA-2006-E-0322 U.S. Patent and Trademark Office to FDA/CDER (HFD-7) Other LET-Letter 2006-12-26T05:00:00Z 2006 12     2008-04-11T23:07:56Z   0 0 090000648045cce0
FDA-2005-P-0313-0004 FDA FDA to Refuse to Approve ANDA or Section 505(b)(2), for Inhalation Drug Products Containing A Combination of the Active Ingredients Albuterol Sulfate & Ipratropium Hydrochloirde Administered by Nebulization for the Treatment of Chronic Pulmonary Obstructive Disorder-CLOSED FDA-2005-P-0313 Petition Denial from FDA CDER to Charles J. Raubicheck Other Denial 2006-12-26T05:00:00Z 2006 12     2024-12-16T16:54:26Z   0 0 0900006480447a06
FDA-2006-E-0506-0002 FDA Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,614,560 FDA-2006-E-0506 Letter from U.S. Patent and Trademark Office to FDA CDER Other Letter(s) 2006-12-26T05:00:00Z 2006 12     2026-01-06T20:55:50Z   0 0 090000648046399d
FDA-2006-E-0506-0001 FDA Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,614,560 FDA-2006-E-0506 Letter from U.S. Patent and Trademark Office to FDA CDER Other Letter(s) 2006-12-26T05:00:00Z 2006 12     2026-01-06T20:53:27Z   0 0 0900006480463997
FDA-2000-V-0069-0001 FDA Laser Light Show FDA-2000-V-0069 FDA/CDRH to Level Entertainment, LLC - Approval for Variance Other Approval for Variance (VRA) 2006-12-26T05:00:00Z 2006 12     2025-07-30T17:21:44Z   0 0 09000064804b00bf
FDA-2006-E-0125-0002 FDA Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,061,703 FDA-2006-E-0125 Request for Certificate of Correction from U.S. Patent and Trademark Office Other Letter(s) 2006-12-26T05:00:00Z 2006 12     2026-01-06T19:13:42Z   0 0 09000064804501c7
FDA-2005-P-0125-0004 FDA Over-the Counter Sale of Modafinil-CLOSED FDA-2005-P-0125 Petition Denial from FDA CDER to James Salsman Other Denial 2006-12-26T05:00:00Z 2006 12     2024-12-13T20:25:39Z   0 0 090000648043fc52
FDA-2006-E-0125-0001 FDA Patent Extension Application for NAMENDA (memantine hydrochloride), U.S. Patent No. 5,061,703 FDA-2006-E-0125 Letter from U.S. Patent and Trademark Office to FDA CDER Other Letter(s) 2006-12-26T05:00:00Z 2006 12     2026-01-06T19:09:03Z   0 0 09000064804501bf
FDA-1999-V-0028-0002 FDA Laser Light Show Projector Model #LP1 FDA-1999-V-0028 Center for Devices and Radiological Health to John's Laser Productions - Approval for Variance Other Approval for Variance (VRA) 2006-12-26T05:00:00Z 2006 12     2025-04-21T20:30:07Z   0 0 09000064804a5c96
FDA-1997-S-0006-0227 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Holistic Therapies Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:07:05Z   0 0 09000064805c995e
FDA-1997-S-0006-0229 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Tronex Company Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:07:03Z   0 0 09000064805c9960
FDA-1997-S-0006-0231 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Calgenex Corporation Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:07:09Z   0 0 09000064805c9962
FDA-1997-S-0006-0230 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Enzymatic Therapy Inc Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:06:57Z   0 0 09000064805c9961
FDA-1997-S-0006-0228 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Tronex Company Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:06:55Z   0 0 09000064805c995f
FDA-1997-S-0006-0226 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Flora Inc Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:07:01Z   0 0 09000064805c995d
FDA-1997-S-0006-0232 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to World Nutrition Inc Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:07:09Z   0 0 09000064805c9963
FDA-1997-S-0006-0225 FDA Dietary Supplements, Courtesy Letters (Letters of Objection) FDA-1997-S-0006 FDA/CFSAN to Enzymatic Therapy Inc Other LET-Letter 2006-12-22T05:00:00Z 2006 12     2008-05-16T22:07:07Z   0 0 09000064805c995c
FDA-2006-P-0346-0004 FDA FDA-2006-P-0346 Corrected Acknowledgement Letter to Endo Pharmaceuticals Inc Other Correction(s) 2006-12-21T05:00:00Z 2006 12     2012-04-18T22:53:07Z   0 0 090000648045f269
FDA-1978-N-0023-0020 FDA Skin Bleaching Drug Products- OPEN FDA-1978-N-0023 Memorandum of Telephone Conversation between FDA/CDER and Venable, LLP Other Memorandum 2006-12-21T05:00:00Z 2006 12     2019-09-16T13:06:41Z   0 0 090000648055fba3
FDA-2004-P-0278-0004 FDA Petition to Require Restaurants to Indicate That the Food they Serve Contains Trans Fat From Partially Hydrogenated Vegetable Oils-CLOSED FDA-2004-P-0278 Citizen Petition Denial from FDA CFSAN to the Center for Science in the Public Interest (CSPI) Other PDN-Petition Denial 2006-12-21T05:00:00Z 2006 12 2006-12-15T05:00:00Z   2025-02-19T16:56:00Z   0 0 090000648047269b
FDA-2002-P-0246-0001 FDA Print Clear, Legible & Intelligible Product Expiration Date-CLOSED FDA-2002-P-0246 Petition Denial from FDA Associate Commissioner for Regulatory Affairs to Auishalom Klammer Other PDN-Petition Denial 2006-12-21T05:00:00Z 2006 12     2024-08-15T13:51:59Z   0 0 090000648049aa59
FDA-2006-N-0543-0019 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Honorable Richard G. Lugar Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2008-04-11T23:15:33Z   0 0 09000064804690aa
FDA-2006-N-0543-0018 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Honorable John Warner - Letter Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2009-02-17T23:03:30Z   0 0 09000064804690a9
FDA-2006-P-0267-0001 FDA Withdrawal of Approval of and recall all available stock of Ziana; CLOSED FDA-2006-P-0267 Acknowledgment Letter from FDA DMB to Emil Tanghetti, MD Other Acknowledgement Letter/Receipt 2006-12-20T05:00:00Z 2006 12     2025-01-27T14:47:27Z   0 0 0900006480457d63
FDA-1978-N-0023-0008 FDA Skin Bleaching Drug Products- OPEN FDA-1978-N-0023 Internal Memo from Jeffery Shuren, FDA/Office of the Commissioner, to FDA/DDM (HFA-305) dated December 19, 2006 Other Memorandum 2006-12-20T05:00:00Z 2006 12     2019-10-11T16:36:58Z   0 0 090000648055f84b
FDA-2006-N-0543-0020 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Kathleen HArner Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2008-04-11T23:15:42Z   0 0 09000064804690ab
FDA-2006-N-0543-0017 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Honorable George Allen - Letter Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2009-02-17T23:01:37Z   0 0 09000064804690a8
FDA-2006-N-0543-0016 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Honorable Evan Bayh Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2008-04-11T23:15:16Z   0 0 09000064804690a7
FDA-2006-N-0543-0013 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Honorable Patty Murray - Letter Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2009-02-19T21:43:10Z   0 0 09000064804690a4
FDA-2006-P-0203-0005 FDA Exclusivity Determination for Risperidone FDA-2006-P-0203 Interim Response from FDA CDER to Mylan Pharmaceuticals, Inc. Other Letter(s) 2006-12-20T05:00:00Z 2006 12     2024-11-21T13:46:24Z   0 0 09000064804510d6
FDA-2006-N-0543-0014 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Kathleen HArner Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2008-04-11T23:15:42Z   0 0 09000064804690a5
FDA-2006-N-0543-0015 FDA Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam FDA-2006-N-0543 FDA to Honorable Rick Santorum Other LET-Letter 2006-12-20T05:00:00Z 2006 12     2008-04-11T23:15:07Z   0 0 09000064804690a6
FDA-2006-P-0267-0002 FDA Withdrawal of Approval of and recall all available stock of Ziana; CLOSED FDA-2006-P-0267 Acknowledgment Letter from FDA DMB to Emil Tanghetti, MD Other Acknowledgement Letter/Receipt 2006-12-20T05:00:00Z 2006 12     2025-01-27T14:48:57Z   0 0 0900006480457d8d
FDA-2006-P-0025-0002 FDA Require ANDA Applicant for Generic of Eloxatin Solution as Reference Drug to Perform Clinical Testing-CLOSED FDA-2006-P-0025 FDA/DDM to Sanofi-aventis US LLP Other ACK-Acknowledgement Letter 2006-12-19T05:00:00Z 2006 12     2008-04-11T23:17:24Z   0 0 0900006480441f21
FDA-2006-P-0025-0001 FDA Require ANDA Applicant for Generic of Eloxatin Solution as Reference Drug to Perform Clinical Testing-CLOSED FDA-2006-P-0025 FDA/DDM to Sanofi-aventis US LLP Other ACK-Acknowledgement Letter 2006-12-19T05:00:00Z 2006 12     2008-04-11T23:17:24Z   0 0 0900006480441ef8
FDA-2006-P-0334-0004 FDA Request that the FDA announce an Advance Notice of Proposed Rulemaking regarding the use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods. FDA-2006-P-0334 Acknowledgment Letter from FDA DMB to Center for Science in the Public Interest Other Acknowledgement Letter/Receipt 2006-12-19T05:00:00Z 2006 12     2025-01-27T16:14:34Z   0 0 090000648045d310
FDA-2006-P-0334-0003 FDA Request that the FDA announce an Advance Notice of Proposed Rulemaking regarding the use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods. FDA-2006-P-0334 Acknowledgment Letter from FDA DMB to Center for Science in the Public Interest Other Acknowledgement Letter/Receipt 2006-12-19T05:00:00Z 2006 12     2025-01-27T16:10:25Z   0 0 090000648045d30f
FDA-2006-P-0387-0003 FDA FDA-2006-P-0387 FDA Interim Reponse to Orchid Healthcare Other LET-Letter 2006-12-18T05:00:00Z 2006 12     2009-04-01T16:00:56Z   0 0 0900006480460607
FDA-2006-V-0221-0001 FDA FDA-2006-V-0221 FDA/DDM to Mountain High Resort Other ACK-Acknowledgement Letter 2006-12-18T05:00:00Z 2006 12     2008-04-11T23:22:27Z   0 0 09000064804520fb
FDA-1995-V-0012-0002 FDA Laser Light Show FDA-1995-V-0012 Laseronics Northwest dba Laseronics Design Interstellar Other VRA-Approval for Variance 2006-12-18T05:00:00Z 2006 12     2013-08-11T02:44:08Z   0 0 090000648055847a
FDA-2006-V-0221-0002 FDA FDA-2006-V-0221 FDA/DDM to Mountain High Resort Other ACK-Acknowledgement Letter 2006-12-18T05:00:00Z 2006 12     2008-04-11T23:22:27Z   0 0 090000648045212b
FDA-2000-V-0217-0003 FDA Laser Light Show FDA-2000-V-0217 FDA Center for Devices and Radiological Health to Laser Wizardry - Approval for Variance Other VRA-Approval for Variance 2006-12-18T05:00:00Z 2006 12     2008-05-06T14:59:45Z   0 0 09000064804d4fb0
FDA-2006-P-0346-0001 FDA FDA-2006-P-0346 Acknowledgement Letter to Endo Pharmaceuticals Inc Other Acknowledgement Letter/Receipt 2006-12-18T05:00:00Z 2006 12     2012-04-18T22:43:25Z   0 0 090000648045f22c
FDA-2005-P-0366-0004 FDA Require that generic version of Wellbutrin XL (bupropion hydrochloride extended-release tablets) meet specific criteria in order to be considered bioequivalent to Wellbutrin XL-CLOSED FDA-2005-P-0366 Petition Approval from FDA/Associate Commissioner for Policy and Planning to Keller and Heckman LLP Other Approval 2006-12-18T05:00:00Z 2006 12     2025-04-24T18:45:27Z   0 0 090000648044af45
FDA-2006-P-0277-0002 FDA Stop All Approvals of Medical Devices Used for Implantable Lens Implants Including, But Not Limited to Phakic IOLs (PIOLs) & Collamar Lenses or to Place a Moratorium on Their Use-CLOSED FDA-2006-P-0277 Acknowledgement Letter from FDA DMB to Michael Patterson Other   2006-12-18T00:00:00Z 2006 12     2025-01-27T15:12:27Z   0 1 090000648045840f
FDA-2006-V-0098-0005 FDA FDA-2006-V-0098 N9NE Group dba Moon Bar - Approval for a Variance Other VRA-Approval for Variance 2006-12-15T05:00:00Z 2006 12     2008-09-09T12:57:35Z   0 0 0900006480444cfb
FDA-2006-E-0197-0001 FDA Patent Extension Application for SPRYCEL (dasatinib), U.S. Patent No. 6,596,746 FDA-2006-E-0197 Letter from U.S. Patent and Trademark Office to FDA CDER Other Letter(s) 2006-12-15T05:00:00Z 2006 12     2025-12-19T00:01:54Z   0 0 0900006480450eec
FDA-2006-P-0010-0003 FDA Refain From Approving all Abbreviated Applications for Generic Enrofloxacin That Purport to Copy Bayer's Baytril 100 Injectable Solution-CLOSED FDA-2006-P-0010 Interim Response from FDA CVM to Sidley Austin LLP Other Letter(s) 2006-12-15T05:00:00Z 2006 12     2024-10-28T17:16:53Z   0 0 090000648044158b
FDA-1978-N-0018-0493 FDA Sunscreen Drug Products -OPEN FDA-1978-N-0018 Letter from FDA/CDER to Schering-Plough Consumer Healthcare Other Letter(s) 2006-12-15T05:00:00Z 2006 12     2019-08-02T16:36:22Z   0 0 090000648055aa60
FDA-2006-V-0098-0006 FDA FDA-2006-V-0098 FDA/CDRH to N9NE Group dba Moon Bar - Variance Attachment B Other VRA-Approval for Variance 2006-12-15T05:00:00Z 2006 12     2008-09-09T14:09:39Z   0 0 0900006480444cfd
FDA-2006-E-0197-0002 FDA Patent Extension Application for SPRYCEL (dasatinib), U.S. Patent No. 6,596,746 FDA-2006-E-0197 Notice of Informalities from U.S. Patent and Trademark Office to Bristol-Myers Squibb Company Other Letter(s) 2006-12-15T05:00:00Z 2006 12     2025-12-19T00:04:01Z   0 0 0900006480450ef7
FDA-2006-P-0404-0002 FDA FDA-2006-P-0404 FDA/CFSAN to Hyman Phelps & McNamara PC Other LET-Letter 2006-12-15T05:00:00Z 2006 12     2008-04-11T23:21:26Z   0 0 0900006480460d51
FDA-2006-V-0098-0004 FDA FDA-2006-V-0098 N9NE Group dba Moon Bar - Variance Attachment A Other VRA-Approval for Variance 2006-12-15T05:00:00Z 2006 12     2008-09-09T14:20:13Z   0 0 0900006480444cf8
FDA-2001-V-0064-0001 FDA Laser light show projector FDA-2001-V-0064 FDA/CDRH Response to Nth Degree Creative - Approval for Variance Other VRA-Approval for Variance 2006-12-15T05:00:00Z 2006 12     2009-05-23T00:49:19Z   0 0 09000064804b8141
FDA-1999-E-0123-0001 FDA Patent Term Extension for Uvadex, U.S. Patent No. 4,999,375 FDA-1999-E-0123 Letter from FDA/CDER to the USPTO Other Letter(s) 2006-12-15T00:00:00Z 2006 12     2025-05-14T15:34:58Z   0 0 09000064804ae996
FDA-2006-N-0107-0003 FDA Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing FDA-2006-N-0107 Duplicate Other LST-List 2006-12-14T05:00:00Z 2006 12     2008-11-18T22:36:08Z   0 0 090000648044f71c
FDA-2006-N-0107-0005 FDA Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing FDA-2006-N-0107 Duplicate Other LST-List 2006-12-14T05:00:00Z 2006 12     2008-11-18T22:40:24Z   0 0 090000648044f720
FDA-2006-P-0214-0001 FDA Stay any action to grant approval for Oxycodone Hydrochloride extended release tablets, ANDA 77-822 FDA-2006-P-0214 Acknowledgment Letter from FDA DMB to Kleinfeld, Kaplan and Becker, LLP Other Acknowledgement Letter/Receipt 2006-12-14T05:00:00Z 2006 12     2024-12-09T14:30:53Z   0 0 0900006480451d15
FDA-2006-P-0214-0002 FDA Stay any action to grant approval for Oxycodone Hydrochloride extended release tablets, ANDA 77-822 FDA-2006-P-0214 Acknowledgment Letter from FDA DMB to Kleinfeld, Kaplan and Becker, LLP Other Acknowledgement Letter/Receipt 2006-12-14T05:00:00Z 2006 12     2024-12-09T14:34:53Z   0 0 0900006480451d47
FDA-2006-P-0271-0001 FDA Determine that the Reference Listed Drug, Hydrochlorothiazide Tablets USP 100 mg, was voluntarily discontinued from sale in the US for reasons other than safety or effectiveness - CLOSED FDA-2006-P-0271 Acknowledgment Letter from FDA DMB to Caraco Pharmaceutical Laboratories, Ltd. Other Acknowledgement Letter/Receipt 2006-12-14T05:00:00Z 2006 12     2025-01-27T15:43:34Z   0 0 090000648045806e
FDA-2006-P-0271-0002 FDA Determine that the Reference Listed Drug, Hydrochlorothiazide Tablets USP 100 mg, was voluntarily discontinued from sale in the US for reasons other than safety or effectiveness - CLOSED FDA-2006-P-0271 Acknowledgment Letter from FDA DMB to Caraco Pharmaceutical Laboratories, Ltd. Other Acknowledgement Letter/Receipt 2006-12-14T05:00:00Z 2006 12     2025-01-27T15:49:44Z   0 0 0900006480458073
FDA-2006-N-0107-0002 FDA Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing FDA-2006-N-0107 Panelists for the Part 15 Public Hearing Other LST-List 2006-12-14T05:00:00Z 2006 12     2013-07-27T20:43:43Z   0 0 090000648044f71a
FDA-2006-N-0107-0004 FDA Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing FDA-2006-N-0107 Part 15 Public Hearing Schedule Other LST-List 2006-12-14T05:00:00Z 2006 12     2013-07-27T20:43:43Z   0 0 090000648044f71e
FDA-1990-S-0006-0159 FDA Generic Drug Speeches & Policy & Procedure Guides FDA-1990-S-0006 Statistical Report - Month of November 2006 Other RPT-Report (outside of agency unless indicated) 2006-12-14T05:00:00Z 2006 12     2008-05-16T23:51:58Z   0 0 09000064805260fa
FDA-2006-P-0068-0003 FDA Stay the potential grant effective approval of ANDA for 77-536 for moexipril hydrochloride tablets FDA-2006-P-0068 Letter from FDA CDER to Schwarz Pharma, Inc. Other Letter(s) 2006-12-14T05:00:00Z 2006 12     2024-12-05T16:13:42Z   0 0 0900006480444446
FDA-2006-P-0145-0002 FDA ANDA Suitability for Propoxyphene Hydrochloride 65 mg and Acetaminophen 325 mg Tablets-CLOSED FDA-2006-P-0145 Acknowledgement Letter FDA DMB to Lachman Consultant Services, Inc. Other Acknowledgement Letter/Receipt 2006-12-14T05:00:00Z 2006 12     2024-12-10T13:39:51Z   0 0 090000648045049f
FDA-2006-P-0073-0003 FDA Approval of any Budesonide Inhalation Suspension Product using Pulmicort Respules FDA-2006-P-0073 Letter from FDA CDER to AstraZeneca, LP [Ropes & Gray] Other Letter(s) 2006-12-12T05:00:00Z 2006 12     2024-10-28T14:00:51Z   0 0 0900006480444589
FDA-2006-E-0320-0002 FDA Patent Extension Application for X-STOP Interspinous Process Decompression System, U.S. Patent No. 6,235,030 FDA-2006-E-0320 Letter from FDA CDER to U.S. Patent and Trademark Offce Other Letter(s) 2006-12-12T05:00:00Z 2006 12     2025-12-19T23:18:55Z   0 0 090000648045cc28
FDA-2006-V-0463-0002 FDA FDA-2006-V-0463 FDA / DDM to LFI International Other ACK-Acknowledgement Letter 2006-12-12T05:00:00Z 2006 12     2008-04-11T23:22:43Z   0 0 0900006480462955
FDA-2006-P-0449-0002 FDA FDA-2006-P-0449 Acknowledgment Letter from FDA DMB to Charles E. Weber Other Acknowledgement Letter/Receipt 2006-12-12T05:00:00Z 2006 12     2024-12-09T17:25:32Z   0 0 0900006480462236
FDA-2006-P-0449-0001 FDA FDA-2006-P-0449 Acknowledgment Letter from FDA DMB to Charles E. Weber Other Acknowledgement Letter/Receipt 2006-12-12T05:00:00Z 2006 12     2024-12-10T02:01:04Z   0 0 0900006480462219
FDA-2006-V-0463-0001 FDA FDA-2006-V-0463 FDA / DDM to LFI International Other ACK-Acknowledgement Letter 2006-12-12T05:00:00Z 2006 12     2008-04-11T23:22:43Z   0 0 090000648046294c
FDA-2006-E-0439-0003 FDA Patent Extension Application for NovoLog insulin aspart (rDNA origin) injection, U.S. Patent No. 5,618,913 FDA-2006-E-0439 Letter from FDA CDER to U.S. Patent and Trademark Office Other Letter(s) 2006-12-12T05:00:00Z 2006 12     2026-01-08T00:50:31Z   0 0 0900006480461ec1
FDA-2006-P-0017-0003 FDA Ban of Carcinogenic Potassium Bromate used in the Breadmaking Process FDA-2006-P-0017 Interim Response Letter from FDA CFSAN to Yoon Ja Kim Other   2006-12-12T00:00:00Z 2006 12     2025-01-30T17:47:15Z   0 1 09000064804416e3
FDA-2006-P-0077-0002 FDA ANDA Suitability for Methotrexate Injection FDA-2006-P-0077 Acknowledgment Letter from FDA DMB to Sicor Pharmaceuticals, Inc. Other Acknowledgement Letter/Receipt 2006-12-11T05:00:00Z 2006 12     2024-12-10T14:56:54Z   0 0 090000648044470e
FDA-2006-P-0334-0001 FDA Request that the FDA announce an Advance Notice of Proposed Rulemaking regarding the use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods. FDA-2006-P-0334 Acknowledgment Letter from FDA DMB to Center for Science in the Public Interest Other Acknowledgement Letter/Receipt 2006-12-11T05:00:00Z 2006 12     2025-01-27T16:06:30Z   0 0 090000648045d2e9
FDA-2006-P-0334-0002 FDA Request that the FDA announce an Advance Notice of Proposed Rulemaking regarding the use of symbols on the principal display panel that would communicate to consumers the healthfulness of foods. FDA-2006-P-0334 Acknowledgment Letter from FDA DMB to Center for Science in the Public Interest Other Acknowledgement Letter/Receipt 2006-12-11T05:00:00Z 2006 12     2025-01-27T16:08:20Z   0 0 090000648045d30d
FDA-2006-P-0077-0001 FDA ANDA Suitability for Methotrexate Injection FDA-2006-P-0077 Acknowledgment Letter from FDA DMB to Sicor Pharmaceuticals, Inc. Other Acknowledgement Letter/Receipt 2006-12-11T05:00:00Z 2006 12     2024-12-10T14:55:59Z   0 0 0900006480444704
FDA-1980-N-0074-0082 FDA Anticaries Drug Products for OTC Human Use; FDA-1980-N-0074 FDA/ORA to Colgate-Palmolive Company Other PDN-Petition Denial 2006-12-11T05:00:00Z 2006 12     2008-05-30T22:52:54Z   0 0 09000064805bb550
FDA-2006-P-0399-0002 FDA FDA-2006-P-0399 Acknowledgment Letter from FDA CDER to Lachman Consultant Services, Inc Other Acknowledgement Letter/Receipt 2006-12-08T05:00:00Z 2006 12     2024-11-25T16:29:15Z   0 0 0900006480460afb
FDA-2006-P-0404-0001 FDA FDA-2006-P-0404 FDA/CFSAN to Hyman, Phelps & McNamara PC for Cargill Other ACK-Acknowledgement Letter 2006-12-08T05:00:00Z 2006 12     2008-04-11T23:21:26Z   0 0 0900006480460d23
FDA-1976-N-0027-0030 FDA OTC Nasal Decongestants FDA-1976-N-0027 Memorandum of Teleconference Between FDA/CDER and Walter N. Kernan, M.D. Yale University School of Medicine Other Memorandum 2006-12-08T05:00:00Z 2006 12     2015-12-14T21:39:42Z   0 0 090000648051b8e7
FDA-2006-P-0399-0001 FDA FDA-2006-P-0399 Acknowledgment Letter from FDA CDER to Lachman Consultant Services, Inc Other Acknowledgement Letter/Receipt 2006-12-08T05:00:00Z 2006 12     2024-11-25T16:28:06Z   0 0 0900006480460adb
FDA-2002-P-0226-0004 FDA Request for Rulemaking on Functional Foods & to Establish Advisory Committee FDA-2002-P-0226 Foods Being Marketed as "Functional Foods" [ Issues and Questions from FR Notice] - Testimony Other TS-Testimony 2006-12-07T05:00:00Z 2006 12     2009-03-18T21:54:57Z   0 0 09000064804974eb
FDA-2002-P-0226-0006 FDA Request for Rulemaking on Functional Foods & to Establish Advisory Committee FDA-2002-P-0226 Statutory and Regulatory Framework for the Safety of Food Ingredients [FDA/CFSAN]- Testimony Other TS-Testimony 2006-12-07T05:00:00Z 2006 12     2009-03-18T21:57:55Z   0 0 09000064804974f3
FDA-2002-P-0226-0005 FDA Request for Rulemaking on Functional Foods & to Establish Advisory Committee FDA-2002-P-0226 Statutory and Regulatory Framework for the Labeling of Food [FDA/CFSAN]- Testimony Other TS-Testimony 2006-12-07T05:00:00Z 2006 12     2009-03-18T21:59:34Z   0 0 09000064804974f1
FDA-2006-P-0280-0002 FDA ANDA Suitability for Propoxyphene Napsylate and Acetaminophen-CLOSED FDA-2006-P-0280 Acknowledgment Letter from FDA DMB to Lachman Consultant Services, Inc. Other Acknowledgement Letter/Receipt 2006-12-07T05:00:00Z 2006 12     2024-12-10T18:24:01Z   0 0 09000064804585e2
FDA-2002-P-0226-0003 FDA Request for Rulemaking on Functional Foods & to Establish Advisory Committee FDA-2002-P-0226 Foods Being Marketed as "Functional Foods" [FDA/CFSAN] - Testimony Other TS-Testimony 2006-12-07T05:00:00Z 2006 12     2009-03-18T22:00:27Z   0 0 09000064804974e8

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);